SMG posts mixed (but roughly in-line) 1Q F2026 results & reaffirms F2026E guidance with leverage expected to be below 4x at year-end; expects to divest Hawthorne for an equity stake in Vireo in 2Q F2026; maintain $72 fair value estimate (FVE)
Today, before the market open, SMG reported 1Q F2026 results, which reflected a top-line decline of ~3.3% to $354.4 million (compared with consensus of $357.7 million) with adjusted EBITDA jumping to $3.0 million (up from $0.9 in the prior period and the consensus loss estimate of ~$11.25 million) as well as an adj. EPS loss from continuing operations of $0.83 (compared with a loss of $1.15 in 1Q F2025 and the consensus loss estimate of $0.97). [Note: the fiscal first quarter is historically a loss-making period that ultimately comprises less than 10% of full-year results, on average, due seasonality.]
The company generated ~$78 million of free cash flow (FCF) in 1Q F2026 and ended the quarter with a net leverage ratio of 4.03x (compared with 4.52x in the prior period, 4.10x at year-end, ~6.0x at the end of F2023, its stepped-down covenant of 4.5x and its ~3.5x internal target.) In terms of management’s balance sheet/cash flow guidance, the company expects to generate ~$275 million of FCF (compared with ~$274 million in F2025), which it expects to drive leverage down into the “high 3’s” at year end (see Exhibit 1 on page 2), even despite an elevated capital spending plan of ~$130 million (compared with ~$97.5 million, $84 million and ~$93 million in F2025-F2023, respectively), in part focused on increased automation of both manufacturing & back-office operations, as well as its better than ~4% annual dividend payout. The company also introduced a new, multi-year $500 million share repurchase program (nearly ~14% of the outstanding shares at current levels) that will be “phased” in through F2026 before ramping up into F2027 as leverage continues to decline.
Additionally, SMG reaffirmed “with full confidence” (and an anecdotal indication of conservatism) the rest of its initial F2026 financial guidance (see Exhibit 1 on page 2) calling for “low-single digit growth” in U.S. Consumer sales, an adj. gross margin of “at least 32%”, “mid-single digit” adj. EBITDA growth (compared with $581 million in F2025 & $510 million in F2024) and adj. earnings per share (EPS) of $4.15-$4.35 (compared with $3.74 in F2025 & $2.29 in F2024).
Notably, the company indicated that the company had signed a memorandum of understating (MOU) to contribute the remainder of Hawthorne, its cannabis-related subsidiary, in return for a reportedly ~13% stake in privately held Vireo Growth, Inc., which is a licensed operator across 10 U.S., including CA, FL, NY. Anecdotally, management indicates the transaction, which is expected to close in 2Q F2026, will be immediately margin accretive (considering it is operating at roughly a breakeven level following a multi-year period of losses, including operating deficits of ~$14 million in F2024 and ~$48 million in F2023). In conjunction with the pending transaction, the company took a non-cash, pre-tax impairment of ~$105 million (i.e., sale price less carrying value).
All told, our base case fair value estimate (FVE) for Scotts Miracle Gro (SMG) remains $72 per share, which assigns de minimis value to its remaining cannabis-related supply asset, Hawthorne, and accounts for corporate costs and net debt (see Exhibit 3 on page 3).
PCS Research Group welcomes and encourages your feedback. Please feel free to call us if we can be of service.